Biosense Webster Completes Enrollment in Pivotal Trial Evaluating PFA and RF Dual Energy Catheter for Patients with Atrial Fibrillation in Europe 19 July 2023
Biosense Webster Begins SmartfIRE Clinical Trial to Evaluate its First Dual Energy Catheter to Treat Atrial Fibrillation 07 March 2023
Biosense Webster Launches HELIOSTAR™ in Europe, the First Radiofrequency Balloon Ablation Catheter, Enabling Physicians to Perform More Efficient Cardiac Ablations 12 October 2022
Biosense Webster Announces Completion of Atrial Fibrillation Cases Using Novel HELIOSTAR™ Balloon Ablation Catheter 28 September 2021
Biosense Webster inspIRE Clinical Study Shows 100% Acute Procedural Success in Initial Data 27 August 2021
Comparing the Effectiveness of Different Catheter Ablation Technologies to Help Atrial Fibrillation (AF) Patients Live ‘Disease Free’ 27 October 2020
Biosense Webster Launches CARTO® 3 System Version 7 and the CARTO PRIME™ Mapping Module to Advance Treatment of Complex Arrhythmias 27 August 2020
Biosense Webster Receives CE Mark Approval for QDOT MICRO®, The World’s First Very High Power, Short Duration Ablation Catheter 13 August 2020
